NFE2L2 and pulmonary arterial hypertension: In support of NRF2-based therapy in PAH, bardoxolone methyl (CDDO-Me), a NRF2 inducer has shown encouraging results in a Phase II study in PAH (https://pulmonaryhypertensionnews.com/2015/10/27/reatas-bardoxolone-methyl-pah-therapy-shows-promise-initial-phase-2-data/).